Professional Documents
Culture Documents
Scandinavian College
of
NeuroPsychopharmacology
SCNP
52nd Annual
Meeting of the
Scandinavian College
of NeuroPsychopharmacology
Oslo – 12-14 April 2011
http://scnp.org
%RDUGPHPEHUV
3UHVLGHQW
3URIHVVRU2OH$$QGUHDVVHQ
2VOR12
3DVW3UHVLGHQW
3URIHVVRU7RUJQ\+6YHQVVRQ
6WRFNKROP6(
6HFUHWDU\
$VVRF3URIHVVRU-HVSHU(NHOXQG
+HOVLQNL),1
7UHDVXUHU
$VVRF3URIHVVRU*UHJHUV:HJHQHU
$DUKXV'.
%RDUGPHPEHUV
$VVRF3URIHVVRU7RYH*XQQDUVVRQ
6WRFNKROP6(
3URIHVVRU$QGUqV0DJQVVRQ
5H\NMDYLN,6
$QGHUV6YHQVVRQ-DQVVHQ
6WRFNKROP6(
&RQJUHVV
3URJUDPPH
78(6'$<$35,/WK
5(*,675$7,2123(16
*HQHUDODVVHPEO\6&13
/81&+
3/(1$5<6&13
3UHVLGHQWVZHOFRPH
2OH$$QGUHDVVHQ2VOR
3/(1$5<6(66,21
*HQHWLFVXVFHSWLELOLW\DQGHQYLURQPHQWDOVWUHVVRUVLQ
SV\FKRVLV
6LU5RELQ00XUUD\/RQGRQ8.
3/(1$5<6(66,21
2[\WRFLQEDODQFLQJDWWDFKPHQWDQGVXVSLFLRXVQHVV"
0RGHUDWRUV&RUW$3HGHUVHQ&KDSHO+LOO86$ 2OH
$$QGUHDVVHQ2VOR
2[\WRFLQ±PHFKDQLVPVRIDFWLRQDQG
SV\FKRORJLFDOHIIHFWV
,QJD1HXPDQQ5HJHQVEXUJ*HUPDQ\
&RQJUHVV
3URJUDPPH
$Q2[\WRFLQ7UHDWPHQW7ULDOLQ6FKL]RSKUHQLD
5HGXFWLRQRI6RFLDO&RJQLWLYH'H¿FLWVDQG
3V\FKRWLF6\PSWRPV
&RUW$3HGHUVHQ&KDSHO+LOO86$
3UHFOLQLFDODQG&OLQLFDO(YLGHQFHIRU2[\WRFLQ¶V
7KHUDSHXWLF(IIHFWVLQ6FKL]RSKUHQLD
.DL0DF'RQDOG6DQ'LHJR86$
&2))((%5($.
3$5$//(/6(66,216
,$'+'DUHZHWUHDWLQJWKHULJKWSDWLHQWV"
0RGHUDWRUV$QQH/LLVYRQ.QRUULQJ8SSVDOD
-HVSHU(NHOXQG+HOVLQNL
(SLGHPLRORJ\'LDJQRVWLFVFRPRUELGLW\DQG
SURJUHVVWRDGXOWKRRG
3nO=HLQHU2VOR
7KHSUREOHPVZLWKWUHDWLQJ$'+'LQVXEVWDQFH
DEXVH
$QGUpV0DJQVVRQ5H\NMDYLN
7UHDWPHQWRI$'+'V\PSWRPV
$QQH/LLVYRQ.QRUULQJ8SSVDOD
&RQJUHVV
3URJUDPPH
,,$XJPHQWDWLRQVWUDWHJLHVLQWUHDWPHQWUHVLVWDQW
GHSUHVVLRQ
0RGHUDWRUV*UHJHUV:HJHQHU$DUKXV 8OULN)0DOW
2VOR
/LJKWH[SRVXUHDQGVOHHSZDNHF\FOHEDVHG
WKHUDSLHV
7LPR3DUWRQHQ+HOVLQNL
$XJPHQWDWLRQE\FRPELQLQJDQWLGHSUHVVDQWDQG
DQWLSV\FKRWLFGUXJV
7RUJQ\+6YHQVVRQ6WRFNKROP
$XJPHQWDWLRQRIDQWLGHSUHVVDQWWUHDWPHQW±D
SUDFWLFDOFOLQLFDODSSURDFK
8OULN)0DOW2VOR
%5($.
3/(1$5<6(66,21
1HZWUHDWPHQWRSWLRQVLQQHXURSV\FKLDWULFGLVRUGHUV
0RGHUDWRUV'DJ$DUVODQG6WRFNKROP2VOR 7RYH
*XQQDUVRQ6WRFNKROP
$QWLSV\FKRWLFVIRUWKHHOGHUO\KRZKDUPIXODUH
WKH\"
'DJ$DUVODQG6WRFNKROP2VOR
$O]KHLPHU¶VGUXJVLQWKHQH[WGHFDGH
1LHOV$QGUHDVHQ6WRFNKROP
&RQJUHVV
3URJUDPPH
268VKRZVHIIHFWRQPHQWDOIDWLJXHLQ
FOLQLFDOWULDO
$UYLG&DUOVVRQ*RWKHQEXUJ
:(/&20(5(&(37,21
5HIUHVKPHQWV
&RQJUHVV
3URJUDPPH
:('1(6'$<$35,/WK
3/(1$5<6(66,21
6&13±/(&785(
0RGHUDWRU7RUJQ\+6YHQVVRQ6WRFNKROP
3V\FKRSKDUPDFRORJ\DQGFRJQLWLRQ
%DUEDUD6DKDNLDQ2[IRUG8.
3/(1$5<6(66,21
(&13(GXFDWLRQDO6\PSRVLXP±1HZDUHDVIRUGUXJ
GHYHORSPHQW
0RGHUDWRUV-HVSHU(NHOXQG+HOVLQNL $UYLG&DUOVVRQ
*RWKHQEXUJ
%LRPDUNHUVWRJXLGHGUXJGHYHORSPHQWLQ
QHXURSV\FKLDWULFGLVRUGHUV±H[DPSOHIURP
$O]KHLPHU¶VGLVHDVH
.DM%OHQQRZ*RWKHQEXUJ
$OWHUDWLRQRIHPRWLRQDOSURFHVVLQJDVDPDUNHU
RIDQWLGHSUHVVDQWDFWLRQ
0LFKDHO%URZQLQJ2[IRUG
1HZJHQHWLFV¿QGLQJVLQSV\FKLDWU\±FDQLW
IDFLOLWDWHGUXJGHYHORSPHQW"
'DYLG$&ROOLHU/RQGRQ
&RQJUHVV
3URJUDPPH
)XWXUHDSSOLFDWLRQVRIPROHFXODULPDJLQJLQGUXJ
GHYHORSPHQW
/DUV)DUGH6WRFNKROP
&2))((%5($.
6$7(//,7(6<0326,80(/,/,//<
3UHVHQWDQGIXWXUHFKDOOHQJHVLQWKHORQJWHUP
PDQDJHPHQWRI6FKL]RSKUHQLD
0RGHUDWRU+XJR$-¡UJHQVHQ%HUJHQ
&KDOOHQJHVLQWKHORQJWHUPPDQDJHPHQWRI
VFKL]RSKUHQLD
6LU5RELQ00XUUD\/RQGRQ8.
5HPRYLQJWKHURDGEORFNV+RZWRRYHUFRPHWKH
EDUULHUVWRDGKHUHQFH
&HFLOLD%UDLQ*RWKHQEXUJ
2ODQ]DSLQHORQJDFWLQJLQMHFWLRQ$UHYLHZRI
FOLQLFDOGDWD
2OH.ULVWLDQ.OHLYHQHV(OL/LOO\6FDQGLQDYLD
/81&+
&RQJUHVV
3URJUDPPH
3/(1$5<6(66,21
/LWKLXPUHYLVLWHG
0RGHUDWRUV*UHJHUV:HJHQHU$DUKXV $QGHUV
6YHQVVRQ6WRFNKROP
7KHKLVWRU\RI/LWKLXPWUHDWPHQW
/DUVYRQ.QRUULQJ8SSVDOD
3UHFOLQLFDOPHFKDQLVPRIDFWLRQ
9LGDU06WHHQ%HUJHQ
/LWKLXPROGDQGQHZHYLGHQFHRQLWVHI¿FDF\LQ
ELSRODUGLVRUGHU
5DVPXV/LFKW$DUKXV
&2))((%5($.
3/(1$5<6(66,21
6&13<281*6&,(17,676<0326,80
0RGHUDWRUV2OH$$QGUHDVVHQ2VORDQG*UHJHUV
:HJHQHU$DUKXV
&RQFRPLWDQW1(7LQKLELWLRQHQKDQFHVWKH
DQWLSV\FKRWLFOLNHHIIHFWRITXHWLDSLQHLQUDWV
DQGHQKDQFHVSUHIURQWDOGRSDPLQHRXWSXWDQG
FRUWLFDO10'$UHFHSWRUPHGLDWHGWUDQVPLVVLRQ
&DUO%M¡UNROP6WRFNKROP
&RQJUHVV
3URJUDPPH
7KHJKUHOLQVLJQDOOLQJV\VWHPLVLQYROYHGLQWKH
FRQVXPSWLRQRIVZHHWVDVZHOODVRIDOFRKRO
(OLVDEHW-HUOKDJ*RWKHQEXUJ
&DUGLRYDVFXODUULVNIDFWRUVGXULQJVHFRQG
JHQHUDWLRQDQWLSV\FKRWLFWUHDWPHQWDUH
DVVRFLDWHGZLWKLQFUHDVHGLPPXQHPDUNHUV
,QJULG'LHVHW2VOR
6HURWRQLQWUDQVSRUWHUJHQHSRO\PRUSKLVP
FKLOGKRRGWUDXPDDQGFRJQLWLRQLQSDWLHQWVZLWK
SV\FKRWLFGLVRUGHUV
0RQLFD$DV2VOR
/LQNLQJF\FOLFQXFOHRWLGHVLJQDOLQJWR
GHSUHVVLRQOLNHEHKDYLRULQUDWV
1LFR/LEHQEHUJ$DUKXV
$FXWHEHKDYLRUDOVWUHVVDIIHFWVWKHUHDGLO\
UHOHDVDEOHSRRORIYHVLFOHVLQSUHIRQWDOIURQWDO
FRUWH[
1LFROHWWD1DYD$DUKXV
3267(56(66,21
5HIUHVKPHQWV
QG&21*5(66',11(5
'HSDUWXUHIURP+RWHO5R\DO&KULVWLDQLD
'LQQHUDW5HVWDXUDQW6SRUWHQ+ROPHQNROOHQ
... at the forefront of
research and education
in the neurosciences
6HUYLHU'DQPDUN$65RVNLOGHYHM'.)UHGHULNVEHUJ
7OI)D[ZZZVHUYLHUGNPDLOLQIR#GNQHWJUVFRP
&RQJUHVV
3URJUDPPH
7+856'$<$35,/WK
3/(1$5<6(66,21
6&13(GXFDWLRQDO/HFWXUH
0RGHUDWRU2OH$$QGUHDVVHQ2VOR
'HSUHVVLRQDQGKHDUWGLVHDVH±FRPPRQ
ELRORJ\"
3RXO9LGHEHFK$DUKXV
3/(1$5<6(66,21
6&13)URQWLHUV/HFWXUH
0RGHUDWRU7RUJQ\+6YHQVVRQ6WRFNKROP
(PRWLRQDOSURFHVVLQJLQGHSUHVVLRQ
*X\*RRGZLQ2[IRUG8.
&2))((%5($.
3/(1$5<6(66,21
(DUO\WUHDWPHQWVWUDWHJLHVLQVFKL]RSKUHQLD±DUHZH
WKHUH\HW"
0RGHUDWRUV,QJULG0HOOH2VOR 7RYH*XQQDUVVRQ
6WRFNKROP
&RQJUHVV
3URJUDPPH
7KHFDVHIRUSUHYHQWLRQLQSV\FKRWLFGLVRUGHUV
,QJULG0HOOH2VOR
&XUUHQWWUHDWPHQWVWUDWHJLHVLQKLJKULVN
SDWLHQWV
6K{Q/HZLV0DQFKHVWHU8.
6WDJHGHSHQGHQWHIIHFWRIRPHJDIDWW\DFLGVLQ
HPHUJLQJSV\FKRVLV
*UHJRU%HUJHU=ULFK6FKZHL]
/81&+
3$5$//(/6(66,216
,6XLFLGH±LPSXOVLYLW\$UHFHQWXSGDWH
0RGHUDWRUV*UHJHUV:HJHQHU$DUKXV /LO7UlVNPDQ
%HQG]/XQG
1HZHYLGHQFHRISUHGLFWRUVRIVXLFLGDOLW\
/LO7UlVNPDQ%HQG]/XQG
,PSXOVLYLW\DQGVHURWRQLQQHXURWUDQVPLVVLRQ
JHQHWLFDQGHQYLURQPHQWDOIDFWRUV
(VSHQ:DOGHUKDXJ2VOR
665,TXHVWLRQUHYLVLWHG
*|UDQ,VDFVVRQ6WRFNKROP
&RQJUHVV
3URJUDPPH
,,7UHQGVDQGWUHDWPHQWLQDGGLFWLRQ
0RGHUDWRUV-¡UJHQ%UDPQHVV2VOR 2OH$
$QGUHDVVHQ2VOR
0HFKDQLVPVLQYROYHGLQHWKDQROVLQWHUDFWLRQ
ZLWKWKHEUDLQUHZDUGV\VWHP
%R6|GHUSDOP*RWKHQEXUJ
&DQWKHVPRNLQJFHVVDWLRQDJHQWYDUHQLFOLQHEH
XVHGIRUWUHDWPHQWRIDOFRKROGHSHQGHQFH"
(OLQ/|I*RWKHQEXUJ
3KDUPDFRORJLFDOWUHDWPHQWIRUGUXJFUDYLQJ
JHWWLQJDQ\ZKHUH"
-¡UJHQ%UDPQHVV2VOR
&21&/86,212)0((7,1*
2OH$$QGUHDVVHQ2VOR
6RFLDO
3URJUDPPH
62&,$/352*5$00(
$SOHDVDQWVRFLDOSURJUDPPHLVDUUDQJHGGXULQJWKHQGDQQXDO
PHHWLQJRIWKH6&13RIIHULQJIUHHDWWHQGDQFHIRUERWKSDUWLFLSDQWV
DQGDFFRPSDQ\LQJSHUVRQV
7XHVGD\$SULODW
:HOFRPHUHFHSWLRQ5HIUHVKPHQWVDWWKH+RWHO5R\DO&KULVWLDQLD
)R\HU
:HGQHVGD\$SULODW
$QDWWHQGHGSRVWHUVHVVLRQZLWKUHIUHVKPHQWLQWKHSRVWHUH[KLELWLRQ
DUHDRIWKH+RWHO5R\DO&KULVWLDQLD
:HGQHVGD\$SULODW'HSDUWXUHIURP+RWHO5R\DO
&KULVWLDQLD
7KH6&13ZLOOFHOHEUDWHLWVQGDQQXDOPHHWLQJDWDGLQQHUWDNLQJ
SODFHLQµ5HVWDXUDQW6SRUWHQ¶+ROPHQNROOHQDW
$WWKHGLQQHUWKH3UHVLGHQWRIWKH6&13ZLOODGGUHVVWKHDXGLHQFH
DQGSUL]HVZLOOEHGLVWULEXWHG
CNS 11.33346S
Om din kollega fortfarande är
djupt deprimerad, vilken
behandling tror du på härnäst?
Oavsett vem du skulle vilja hjälpa
är behandlingsresultaten ofta
nedslående: Alltför många med
depression svarar inte tillräckligt
bra på första linjens behandling.
Du funderar och funderar.
Vad kan fungera? Vad är klokast?
Referenser: www.fass.se, Bauer M, et al., Journal of Affective Disorders 127 (2010) 19–30
Seroquel® Depot (quetiapin), Rx, F, depottablett 50 mg, 150 mg, 200 mg, 300 mg, 400 mg. Farmakologisk grupp: N05AH04. Indikationer: Tilläggsbehandling av depressiva episoder hos patienter med egentlig depression (MDD) som erhållit ett subop-
timalt svar på antidepressiv monoterapi. Behandling av måttliga till svåra maniska episoder och egentlig depressionsepisod vid bipolär sjukdom. Underhållsbehandling för att förhindra återfall i skov vid bipolär sjukdom hos patienter som tidigare svarat
på behandling med quetiapin under maniska eller depressiva episoder. Schizofreni. Underhållsbehandling för patienter med schizofreni i stabil sjukdomsfas. Rekommenderad dosering, en gång per dag, till natten: Vid tilläggsbehandling för egentlig
depression sågs antidepressiv effekt vid 150 och 300 mg/dag (insättning på fyra dagar, 50 mg dag 1 och 2 samt 150 mg dag 3 och 4). Vid bipolär depression 300 mg/dag (insättning på fyra dagar; 50 mg dag 1, 100 mg dag 2, 200 mg dag 3, 300 mg dag
4). Vid bipolär mani och schizofreni 600 mg/dag (insättning på två dagar; 300 mg dag 1, 600 mg dag 2). Seroquel Depot har ej indikation för behandling av barn och ungdomar under 18 år. För fullständig information om kontraindikationer, försiktighet,
biverkningar, pris och dosering, se www.fass.se. SPC 2010-10-22
AstraZeneca AB AstraZeneca Sverige 151 85 Södertälje Tel 08-553 260 00 www.astrazeneca.se www.compaz.se
)RUQRWHV
$FNQRZOHGJHPHQW
$WWKHQG$QQXDO0HHWLQJRIWKH6&13WKH%RDUGZLVKHV
WRDFNQRZOHGJHWKHVXSSRUWIURP/XQGEHFNDQG6HUYLHUHQDEOLQJ
6&13WRLQYLWHVSHDNHUVRIKLJKHVWLQWHUQDWLRQDOVWDQGDUGVWRRXU
PHHWLQJ
)XUWKHUZHDFNQRZOHGJHWKHVXSSRUWIURP(OL/LOO\E\VSRQVRULQJ
WKHVDWHOOLWHV\PSRVLXP
7KH%RDUGRIWKH6&13DOVRZLVKHVWRDFNQRZOHGJHWKDW$VWUD
=HQHFDKDVPDGHLWSRVVLEOHIRUWKH6&13WRLQYLWH\RXQJVFLHQWLVWV
WRSDUWLFLSDWHLQDFRPSHWLWLRQIRUDQRUDOSUHVHQWDWLRQLQ<RXQJ
6FLHQWLVWV6\PSRVLXPZKHUHWKHZLQQHURIWKHFRPSHWLWLRQZLOO
UHFLYHµ7KH6&13$VWUD=HQHFD$ZDUGWR<RXQJ6FLHQWLVWV¶
7KLVLQLWLDWLYHKDVGHYHORSHGLQWRDPRVWYDOXDEOHWUDGLWLRQRIWKH
6&13$QQXDOPHHWLQJVDQGKDVDGGHGYHU\PXFKWRVWLPXODWLQJ
\RXQJVFLHQWLVWVLQWKHLUSHUIRUPDQFHZKHQSDUWLFLSDWLQJLQVFLHQWL¿F
PHHWLQJV
:HDOVRDFNQRZOHGJH-DQVVHQZKRVXSSRUWWKH3RVWHU$ZDUG
:LWKRXWWKHVHVSRQVRUVKLSVZHZRXOGQRWKDYHUHDFKHGWKHKLJK
VWDQGDUGRIWKHPHHWLQJ
)LQDOO\ZHZLVKWRH[SUHVVRXUVLQFHUHWKDQNVWR(&13IRU
VSRQVRULQJWKH(&13VFLHQWL¿FV\PSRVLXP
2QEHKDOIRIWKH%RDUGRIWKH6&13
<RXUVVLQFHUHO\
2OH$$QGUHDVVHQ3UHVLGHQW